Investors may listen to the call by dialing (844) 825-4408 from
To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the event.
About bluebird bio, Inc.
bluebird bio is pioneering gene therapy with purpose. From our
bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in
ZYNTEGLO and LentiGlobin are trademarks of bluebird bio.
The full common name for ZYNTEGLO: A genetically modified autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene.
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s plans and expectations for the
commercialization for ZYNTEGLO® (autologous
CD34+ cells encoding βA-T87Q-globin gene, formerly LentiGlobin™ in TDT)
to treat TDT, and the potential implications of clinical data for
patients. Any forward-looking statements are based on management’s
current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include, but
are not limited to: the risk that the efficacy and safety results from
our prior and ongoing clinical trials of ZYNTEGLO will not continue or
be repeated in our ongoing or planned clinical trials of ZYNTEGLO; the
risk that the current or planned clinical trials of ZYNTEGLO will be
insufficient to support regulatory submissions or marketing approval in
the US, or for additional patient populations in the EU; the risk that
the production of HbAT87Q may not be sustained over extended periods of
time; and the risk that we may not secure adequate pricing or
reimbursement to support continued development or commercialization of
ZYNTEGLO following regulatory approval. For a discussion of other risks
and uncertainties, and other important factors, any of which could cause
our actual results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in our most recent
Form 10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the
Source: bluebird bio, Inc.